Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolonged Artemether-Lumefantrine + Primaquine for Malaria
NCT03241901Phase 4Completed
- Sponsor
- Muhimbili University of Health and Allied Sciences
- Start
- Jul 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of artemether, lumefantrine and primaquine in Plasmodium falciparum malaria (2 arms), sponsored by Muhimbili University of Health and Allied Sciences. Primary endpoint: Parasite Clearance Times at 7 days. Started Jul 2017; status: completed.
02
Drugs
artemetherlumefantrineprimaquine
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT03241901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03241901.